In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs)

Inflammation Research

Volumn 50, Issue 5, 2001, Pages 262-269

  Dannhardt, G ^a   Ulbrich, H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

BAECs; Cyclooxygenase 1 2; NSAIDs; Whole cell in vitro test system

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; ACECLOFENAC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; INDOMETACIN; LIPOXYGENASE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; POLYCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CATTLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ANIMALS; AORTA, THORACIC; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; BLOTTING, WESTERN; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; ISOENZYMES; KINETICS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SPECTROPHOTOMETRY, ULTRAVIOLET; TETRADECANOYLPHORBOL ACETATE;

EID: 0035012251     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050752     Document Type: Article

References (30)

1. [1] Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsiveness gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
2. [2] Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxy-genase homologue. J Biol Chem 1991; 266: 12866-72.
3. [3] De Witt DL. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta 1991; 1083: 121-34.
4. [4] Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40.
5. [5] Kömhoff M, Gröne HJ, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460-68.
6. [6] Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS-Lett 1996; 390: 165-9.
7. [7] Parfenova H, Eidson TH, Leffler CW. Upregulation of COX-2 in cerebral microvascular endothelial cells by smooth muscle cell signals. Am J Physiol 1997; 273: C277-88.
8. [8] Zimmermann K, Weber AA, Sarbia M, Schrör K. Cyclooxygenase-2 is constitutively Expressed in Stomach Mucosa. Arch of Pharm 1998; 357: 33.
9. [9] Dannhardt G, Lehr M. In-vitro Evaluation of 5-Lipoxygenase and Cyclooxygenase Inhibitors using Bovine Neutrophils and Platelets and HPLC. J Pharm Pharmacol 1992; 44: 419-24.
10. [10] Dannhardt G, Flemmer L, Hartmann RW, Kleber A, Schulze E. Spectrofluorimetric Quantification of Malondialdehyde for Evaluation of Cyclooxygenase-1/Thromboxane Synthase Inhibition. Arch. Pharm. Med. Chem. 1998; 331: 359-64.
11. [11] Dannhardt G, Kreher M, Nowe U, Pies A. Method for Testing Non-Steroidal Anti-Inflammatories: The Modified Hen's Egg Chorioallantoic Membrane Test (HET-CAM Test) Compared to Other Procedures. Arch. Pharm. Med. Chem. 1996; 329: 301-10.
12. [12] Mitchell JA, Akarasereenont P, Thiemermann C, Flower JF, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 11693-97.
13. [13] Wohlfeil ER, Campbell WB. 25-Hdroxycholesterol enhances eicosanoid production in cultered bovine coronary artery endothelial cells by increasing prostaglandin G/H synthase-2. Biochim Biophys Acta 1997; 1345: 109-20.
14. [14] Gimbrone MA. Culture of vascular endothelium. In: Spaet TH. editor Progress in Hemostasis and Thrombosis. vol. 3. New York: Grune and Stratton, 1976: 1-28.
15. [15] Jaffe EA, Hayer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-64.
16. [16] Li JJ, Anderson GD, Burton EG, Cogbum JN, Collins JT, Garland DJ et al. 1,2-Diarylcyclopentenes as selective cyclo-oxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem 1995;38:4570-8.
17. [17] Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 1994; 113: 1522-8.
18. [18] Tordjman C, Serkiz B, Rambaud F, Bonnet J, Volland JP. High performance liquid chromatographic quantitation of cyclooxygenase and lipoxygenase metabolites of arachidonic acid from rat polymorphonuclear leukocytes. J Chromatogr. 1990; 532: 135-43.
19. [19] Ibe BO, Falck JR, Johnson AR, Campbell WB. Regulation of prostacyclin and HETEs in human endothelial cells. Am J Physiol 1989; 256: C 1168-75.
20. [20] Hollenberg SM, Tong W, Shelhamer JH, Lawrence M, Cunnion RE. Eicosanoid production by human aortic endothelial cells in response to endothelin. Am J Physiol 1994; 267: H2290-6.
21. [21] Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR. Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol 1995; 273: 121-8.
22. [22] Miralpeix M, Camacho M, Lopez-Belmonte J, Canalias F, Beleta J, Palacios JM et al. Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological characterization. Br J Pharmacol 1997; 121: 171-80.
23. [23] Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endo-peroxidesynthases. J Pharmacol Exp Ther 1994; 271: 1705-12.
24. [24] Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration. Inflamm Res 1998; 47: 102-6.
25. [25] Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W. et al Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997; 121: 105-17.
26. [26] Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel, PP et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci 2000; 97: 925-30.
27. [27] Yamazaki R, Kawai S, Matsuzaki T, Kaneda N, Hashimoto S, Yokokura T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997; 329: 181-7.
28. [28] Feinmark SJ, Cornicelli JA. Is there a role for 15-lipoxygenase in atherogenesis? Biochem Pharmacol 1997; 54: 953-59.
29. [29] Liagre B, Vergne P, Rigaud M, Beneytout JL. Arachidonate 15-lipoxygenase of reticulocyte-type in human rheumatoid arthritis type B synoviocytes and modulation of its activity by proinflammatory cytokines. J Rheumatol 1999; 26: 1044-51.
30. [30] Dailey LA, Imming P. 12-Lipoxygenase: Classification, Possible Therapeutic Benefits from Inhibition and Inhibitors. Curr Med Chem 1999; 6: 389-98.